British Columbia Children's Hospital Research Institute, Vancouver, British Columbia, Canada; Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Cell Mol Gastroenterol Hepatol. 2023;15(2):425-438. doi: 10.1016/j.jcmgh.2022.10.004. Epub 2022 Oct 13.
BACKGROUND & AIMS: Increased intestinal permeability is seen in a variety of inflammatory conditions such as enteric infections and inflammatory bowel disease. Because barrier function can provide a key biomarker of disease severity, it often is assayed in animal models. A common methodology involves gavaging mice with fluorescein isothiocyanate-conjugated dextran (FITC-D), followed by cardiac puncture to assay plasma fluorescence on a spectrophotometer. Although the FITC-D method is relatively simple, its sensitivity is limited and enables only a single measurement because the test requires killing the subject. Herein, we describe a novel flow cytometry-based method of intestinal permeability measurement based on detection of orally gavaged ovalbumin (OVA) that leaks out of the gut. Our approach uses minute blood volumes collected from the tail vein, permitting repeated testing of the same subject at multiple time points. By comparing this assay against the gold standard FITC-D method, we show the expanded utility of our OVA assay in measuring intestinal permeability.
We directly compared our OVA assay against the FITC-D assay by co-administering both probes orally to the same animals and subsequently using their respective methodologies to measure intestinal permeability by detecting probe levels in the plasma. Permeability was assessed in mice genetically deficient in intestinal mucus production or glycosylation. In addition, wild-type mice undergoing dextran sodium sulfate-induced colitis or infected by the enteric bacterial pathogen Citrobacter rodentium also were tested.
The OVA assay showed very high efficacy in all animal models of intestinal barrier dysfunction tested. Besides identifying intestinal barrier dysfunction in mice with impaired mucin glycosylation, the assay also allowed for repeated tracking of intestinal permeability within the same animal over time, providing data that cannot be easily acquired with other currently applied methods.
The OVA assay is a highly sensitive and effective method of measuring intestinal permeability in mouse models of barrier dysfunction and experimental colitis.
在多种炎症性疾病中,如肠内感染和炎症性肠病,会出现肠道通透性增加。由于屏障功能可以提供疾病严重程度的关键生物标志物,因此通常在动物模型中进行检测。一种常见的方法是用荧光素异硫氰酸酯-葡聚糖(FITC-D)灌胃小鼠,然后通过心脏穿刺在分光光度计上检测血浆荧光。尽管 FITC-D 方法相对简单,但由于该测试需要处死实验动物,因此其灵敏度有限,只能进行单次测量。在此,我们描述了一种基于流式细胞术的新型肠道通透性测量方法,该方法基于检测从肠道漏出的口服给予的卵清蛋白(OVA)。我们的方法使用从小鼠尾静脉采集的微量血液样本,允许在多个时间点对同一实验动物进行重复测试。通过将该测定法与 FITC-D 金标准方法进行比较,我们证明了我们的 OVA 测定法在测量肠道通透性方面具有更广泛的用途。
我们通过同时将两种探针口服给予同一动物,并随后使用各自的方法通过检测血浆中的探针水平来测量肠道通透性,直接将我们的 OVA 测定法与 FITC-D 测定法进行比较。我们在肠道黏液产生或糖基化缺陷的基因敲除小鼠以及接受葡聚糖硫酸钠诱导结肠炎或感染肠道细菌病原体柠檬酸杆菌的野生型小鼠中进行了通透性评估。
OVA 测定法在所有测试的肠道屏障功能障碍动物模型中均显示出非常高的功效。除了在黏液糖基化受损的小鼠中鉴定出肠道屏障功能障碍外,该测定法还允许在同一动物体内随时间重复跟踪肠道通透性,提供了其他目前应用方法难以获得的数据。
OVA 测定法是一种非常敏感和有效的测量肠道屏障功能障碍和实验性结肠炎小鼠模型中肠道通透性的方法。